FDA Approval Alert: The Need-to-Know | Ensartinib in Metastatic ALK-Positive NSCLC

In December 2024, the FDA approved ensartinib as a treatment for adult patients with metastatic or locally advanced ALK-positive non–small cell lung cancer.

Data from the phase 3 eXalt3 trial support the approval of ensartinib in adult patients with metastatic ALK-positive non–small cell lung cancer.
FDA Approves Ensartinib in Metastatic ALK-Positive NSCLC
Article
Dec 18, 2024 9:05 PM
Data from the phase 3 eXalt3 trial support the approval of ensartinib in adult patients with metastatic ALK-positive non–small cell lung cancer.